Osimert 80 MG (Osimertinib)

Basic Product Information of Osimert 80 MG (Osimertinib)

How Osimert 80 MG (Osimertinib) Works: Third-Generation EGFR Inhibition Mechanism

Osimertinib, the active ingredient in Osimert 80 MG, is a third-generation, irreversible, mono-anilino-pyrimidine EGFR tyrosine kinase inhibitor (EGFR-TKI) that covalently binds to cysteine 797 (Cys797) in the ATP-binding pocket of the EGFR kinase domain. Under normal physiology, the epidermal growth factor receptor (EGFR) mediates cell proliferation and survival through ligand-dependent activation. When somatic mutations occur in the EGFR gene, including exon 19 deletions (Ex19del) and exon 21 L858R point mutations, the resulting mutant receptors are constitutively activated and drive uncontrolled tumor cell proliferation in non-small cell lung cancer (NSCLC) without requiring ligand binding.

Osimertinib irreversibly inhibits all three clinically relevant EGFR mutant forms: the sensitizing mutations Ex19del and L858R that drive NSCLC at diagnosis, and the acquired resistance mutation T790M (threonine-to-methionine substitution at position 790) that develops in approximately 50% of patients whose disease progresses after first- or second-generation EGFR-TKI therapy. The T790M mutation introduces steric hindrance at the kinase binding pocket that prevents first-generation TKIs (erlotinib, gefitinib) and second-generation TKIs (afatinib, dacomitinib) from binding effectively. Osimertinib overcomes this resistance by forming a covalent bond that does not depend on deep pocket access, maintaining sub-nanomolar potency against all three mutant forms while exhibiting approximately 200-fold selectivity for mutant EGFR over wild-type EGFR. This mutant selectivity substantially reduces skin and gastrointestinal toxicity compared with earlier-generation agents. Oncologists building a comprehensive treatment plan can review complementary targeted agents within the oncology medicines catalog at Mediaid Pharmacy.

In the pivotal FLAURA trial (phase III, first-line, 556 patients), osimertinib demonstrated a median progression-free survival (PFS) of 18.9 months versus 10.2 months for comparator first-generation EGFR-TKIs (hazard ratio 0.46; 95% CI 0.37 to 0.57; p less than 0.001), with a statistically significant overall survival (OS) benefit of 38.6 months versus 31.8 months (hazard ratio 0.80; 95% CI 0.64 to 1.00; p = 0.046). In the AURA3 trial (T790M-positive second-line setting, 419 patients), osimertinib produced an objective response rate (ORR) of 71% versus 31% for platinum-pemetrexed chemotherapy, with a median PFS of 10.1 months versus 4.4 months (hazard ratio 0.30; 95% CI 0.23 to 0.41). Osimertinib also demonstrates significant intracranial activity attributed to its ability to cross the blood-brain barrier (BBB), achieving a CNS ORR of 66% versus 43% in FLAURA, making it the preferred first-line agent for EGFR-mutated NSCLC patients with brain metastases.

Approved Indications of Osimertinib (Reference Label for Osimert 80 MG)

Osimertinib, the active ingredient in Osimert 80 MG, was the first third-generation EGFR-TKI to receive regulatory approval across the first-line, adjuvant, and T790M resistance settings, establishing it as the backbone of EGFR-mutated NSCLC treatment across the full disease continuum from post-surgical cure-intent therapy to advanced metastatic disease. Prescribers should confirm the exact approved indications for their jurisdiction using the locally applicable Osimert product label or the Tagrisso originator reference label.

Key Clinical Benefits of Osimert 80 MG (Osimertinib)

Dosage and Administration of Osimert 80 MG (Osimertinib)

Clinical Monitoring Requirements During Osimert 80 MG (Osimertinib) Treatment

Structured clinical monitoring is mandatory throughout osimertinib therapy. Interstitial lung disease (ILD) and pneumonitis are the most clinically serious toxicities, occurring in approximately 3.3% of patients in FLAURA, with 0.4% grade 3 or higher events. Any patient presenting with new or worsening respiratory symptoms including cough, dyspnea, or fever during osimertinib therapy requires urgent radiographic evaluation. Osimertinib must be withheld promptly for any suspected ILD and permanently discontinued for confirmed ILD of any grade.

Cardiac monitoring is required throughout treatment. A baseline electrocardiogram (ECG) and electrolyte panel (potassium, magnesium) must be obtained before starting osimertinib and corrected if abnormal. QTc prolongation greater than 500 msec or greater than 60 msec from baseline requires treatment interruption; osimertinib should not be restarted until QTc recovers to less than 481 msec, and must be permanently discontinued for QTc prolongation with life-threatening arrhythmia or torsades de pointes. Osimertinib is contraindicated in patients with congenital long QT syndrome. Left ventricular ejection fraction (LVEF) should be assessed at baseline in patients with cardiac risk factors; cardiomyopathy has been reported in fewer than 2% of patients, and LVEF re-assessment should be performed if cardiac symptoms develop during treatment. Liver function tests (ALT, AST, bilirubin) should be evaluated periodically. Skin toxicities including rash, dry skin, and paronychia are common and may require topical management; grade 3 skin reactions require dose interruption and reduction. On radiological or clinical progression during osimertinib therapy, repeat tissue or liquid biopsy for on-target resistance mechanisms (C797S mutation) and off-target resistance mechanisms (MET amplification, HER2 amplification, RAS mutations, and histological transformation to small cell lung cancer) is recommended to guide subsequent treatment selection.

Drug Interactions and Important Safety Information for Osimert 80 MG (Osimertinib)

Osimertinib is primarily metabolized by CYP3A4, and co-administration with CYP3A4-modifying agents significantly alters osimertinib plasma exposure. Strong CYP3A4 inducers, including rifampicin, carbamazepine, phenytoin, and St. John’s Wort, reduce osimertinib steady-state AUC by approximately 78% when co-administered with rifampicin 600 mg once daily; concurrent use must be avoided. If a strong CYP3A4 inducer cannot be avoided, increasing the osimertinib dose from 80 mg to 160 mg once daily may be considered, with a return to 80 mg once daily within three weeks of discontinuing the inducer. Moderate CYP3A4 inducers such as efavirenz, bosentan, and modafinil may also reduce osimertinib exposure, and caution with close clinical monitoring is required. Strong CYP3A4 inhibitors including itraconazole, ketoconazole, clarithromycin, and grapefruit products do not produce a clinically significant increase in osimertinib AUC, and no dose adjustment is required for concurrent use of strong CYP3A4 inhibitors.

Osimertinib inhibits BCRP (breast cancer resistance protein) in the gut wall and may increase plasma concentrations of BCRP substrates, including rosuvastatin. Monitor patients for rosuvastatin-associated myopathy if co-administration is required. Osimertinib also inhibits OCT1 (organic cation transporter 1) and may increase exposure to OCT1 substrates such as metformin; monitor for signs of metformin toxicity. Because osimertinib prolongs the QTc interval, concurrent use of other QT-prolonging agents, including antiarrhythmics (amiodarone, sotalol), antipsychotics, and fluoroquinolone antibiotics, increases the risk of ventricular arrhythmia; avoid concurrent use where possible and correct electrolyte abnormalities before and during osimertinib treatment. Women of childbearing potential must use highly effective contraception during treatment and for six weeks after the final dose. Male patients with female partners of childbearing potential must use condom contraception during treatment and for four months after the final dose; osimertinib may impair male fertility, and this effect may be irreversible. Breastfeeding must be discontinued during treatment and for two weeks after the final dose due to the potential for serious adverse reactions in nursing infants.

Side Effects and Precautions of Osimert 80 MG (Osimertinib)

Who Should Use Osimert 80 MG (Osimertinib)?

Osimert 80 MG (Osimertinib) is prescribed for adult patients with non-small cell lung cancer (NSCLC) confirmed to harbor sensitizing EGFR mutations (exon 19 deletions or exon 21 L858R substitutions) in the first-line locally advanced or metastatic setting; adult patients with stage IB to IIIA NSCLC harboring EGFR exon 19 deletion or L858R mutations who have undergone complete surgical resection in the adjuvant setting; and adult patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC whose disease progressed on or after prior EGFR-TKI therapy. Eligibility requires biomarker confirmation by a validated assay such as next-generation sequencing (NGS), cobas EGFR Mutation Test, or real-time PCR applied to tumor tissue or plasma (liquid biopsy). For patients with brain metastases at diagnosis, osimertinib is the preferred first-line EGFR-TKI choice given its demonstrated intracranial efficacy and blood-brain barrier penetration. Prescriptions are initiated and overseen by medical oncologists or thoracic oncologists experienced in precision oncology and biomarker-guided targeted therapy for lung cancer. Patients who require a broader cancer care strategy can review Mediaid Pharmacy’s oncology specialty medicines range for a full selection of targeted agents and supportive therapies across diverse tumor types.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Osimert 80 MG (Osimertinib)

Mediaid Pharmacy is a Dhaka-based supplier of oncology and specialty medicines with worldwide shipping. Osimert 80 MG (Osimertinib) is available as 80 mg tablets in a 30’s pack, covering the full standard once-daily adult dosing requirement, and all orders are supported by pricing quotations, stock confirmation, regulatory documentation, and shipment tracking. Hospitals, oncology clinics, distributors, and patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding Osimert 80 MG Osimertinib availability, pricing, and international delivery logistics. Buyers who require several cancer medicines within a single consignment can review the full oncology medicine collection at Mediaid Pharmacy before requesting a combined quotation.

Why Choose Osimert 80 MG (Osimertinib) from Mediaid Pharmacy?

Osimert 80 MG (Osimertinib) gives oncology teams a third-generation EGFR-TKI backed by landmark clinical data from the FLAURA, ADAURA, and AURA3 trials, including a median PFS of 18.9 months and an OS of 38.6 months in first-line EGFR-mutated NSCLC, a 5-year DFS rate of 89% in resected stage II to IIIA disease, and an ORR of 71% in T790M-positive second-line NSCLC. The 80 mg once-daily tablet formulation in a 30’s pack simplifies patient adherence, and a defined dose reduction to 40 mg once daily provides a clear adverse reaction management pathway. Mediaid Pharmacy supplies Osimert 80 MG with complete product specifications, direct oncology specialist support, and worldwide shipping. Every order is initiated through a prescription-based inquiry to ensure supply is aligned with verified clinical need. To compare osimertinib with other targeted agents or to source additional cancer therapies for a comprehensive treatment plan, visit the Mediaid Pharmacy oncology medicines section, then contact our team for a personalized quotation.

Frequently Asked Questions About Osimert 80 MG (Osimertinib)